Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
NCT06282978
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma in Relapse
Interventions
DRUG:
Elranatamab (PF-06863135)
Sponsor
PETHEMA Foundation